中国药物警戒 ›› 2024, Vol. 21 ›› Issue (3): 329-334.
DOI: 10.19803/j.1672-8629.20230635

• 安全与合理用药 • 上一篇    下一篇

106例安罗替尼临床应用的合理性与安全性分析

刘琦1,2, 张玉凤2, 罗皓2, 李歆1,3,*   

  1. 1南京医科大学药学院, 江苏 南京 211166;
    2南京医科大学康达学院附属涟水人民医院药剂科,江苏 涟水223400;
    3南京医科大学全球健康中心,江苏 南京 211166
  • 收稿日期:2023-10-09 出版日期:2024-03-15 发布日期:2024-03-18
  • 通讯作者: *李歆,男,博士,教授·博导,临床药学与药物经济学。E-mail: xinli@njmu.edu.cn
  • 作者简介:刘琦,女,在读硕士,主管药师,临床药学。
  • 基金资助:
    国家自然科学基金资助项目（72074123）

Analysis of the rationality and safety of clinical application of anrotinib in a hospital

LIU Qi1,2, ZHANG Yufeng2, LUO Hao2, LI Xin1,3,*   

  1. 1School of Pharmacy, Nanjing Medical University, Nanjing Jiangsu 211166, China;
    2Department of Pharmacy, Lianshui People’s Hospital Affiliated to the School of Kang Da of Nanjing Medical University, Lianshui Jiangsu, 223400, China;
    3Center for Global Health, School of Public Health, Nanjing Jiangsu Medical University, Nanjing Jiangsu 211166, China
  • Received:2023-10-09 Online:2024-03-15 Published:2024-03-18

PDF (PC)

152

摘要： 目的 分析安罗替尼临床应用情况,对其进行合理性和安全性评价,规范安罗替尼临床应用。方法 选取某院2022年1月1日至2023年6月30日临床应用安罗替尼的患者106例,共306例次含安罗替尼治疗方案的用药信息,对安罗替尼临床应用合理性和安全性进行回顾性分析。结果 306例次治疗中,用药不合理89例次（29.08%）,不合理类型分别为联合用药不合理47例次（15.36%）、超适应证21例次（6.86%）、用法用量不合理19例次（6.21%）、禁忌用药2例次（0.65%）。发生药品不良反应358例次,不良反应主要累及系统-器官排名前5位分别是消化系统疾病（30.73%）、代谢及营养类疾病（16.48%）、血液及淋巴系统疾病（13.41%）、心血管系统疾病（9.22%）、出血（5.31%）。结论 某院安罗替尼临床应用存在部分不合理现象,医院及相关质控部门应依据安罗替尼说明书、国内外最新的指南和共识规范安罗替尼临床应用管理,加强用药监护,重视其不良反应,提高安罗替尼用药安全性。

关键词: 安罗替尼, 合理性, 安全性, 不良反应, 临床药师, 用药监护

Abstract: Objective To investigate the clinical application of anlotinib in a hospital and evaluate the rationality and safety of related medications, in order to standardize the clinical application of anlotinib. Methods To collect information on 106 patients with clinical application of amilorotinib in a county-level general hospital from January 1, 2022 to June 30, 2023, who received a total of 306 doses of amilorotinib-containing regimens, and to conduct a retrospective analysis of the reasonableness and safety of the clinical application of anlotinib. Results Among the 306 treatments, 89 cases (29.08%) of medication were irrational, and the types of irrationality were 47 cases (15.36%) of irrationality in combination of medication, 21 cases (6.86%) of over-indications, 19 cases (6.21%) of irrationality in dosage, and 2 cases (0.65%) of prohibited use of medication. There were 358 cases of adverse drug reactions (ADR) found in these medical records. The top five organ-system injury were diseases of the digestive system (30.73%), Metabolic and Nutritional Diseases (16.48%), diseases of the blood and lymphatic system (13.41%),diseases of the cardiovascular system (9.22%) and bleeding (5.31%). Conclusion Some irrationality in the clinical use of anrotinib in the hospital, the hospital and relevant quality control department should prescribe and rationally use anlotinib standardize the instructions of anlotinib, the latest domestic and international guidelines and consensus, strengthen the monitoring of medication, evaluate the adverse reactions, and improving the safety of anrotinib.

Key words: anlotinib, rationality, safety, adverse reactions, clinical pharmacist, medication monitoring

中图分类号: